Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of KH607 in Healthy Volunteers
NCT06393803Phase 1Recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KH607 in postpartum depression (PPD) and major depressive disorder (MDD) (11 arms), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoints: 12-lead ECGs, Physical Examination and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
KH607
03
Conditions
postpartum depression (PPD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06393803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393803.